



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 14 Mar 2022 (#10)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

- **Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office) not later than 31 March 2022.** For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.
 - FHMS contact: cdevries@sun.ac.za
 - Stellenbosch Campus contact lizelk@sun.ac.za.

Link to the training: https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html

- **[NOT-OD-21-110](#) Implementation of Changes to the Biographical Sketch and Other Support Format Page.** This notice describes implementation of the updated Other Support and Biosketch format pages and associated instructions, as outlined in [NOT-OD-21-073](#). **ScienCV:** <https://www.ncbi.nlm.nih.gov/sciencv/>
- **[NOT-CA-22-061](#) Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional).** The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. First Estimated Application Due Date: July 15, 2022.
- **[NOT-AI-22-039](#) 2022 NIAID Omnibus Broad Agency Announcement HHS-NIH-NIAID-BAA2022-1 Now Available.** The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, NIH, of the DHHS is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the Division of Microbiology and Infectious Diseases (DMID), NIAID.

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-104](#)

Type: D43

Application Due Date: 13 July 2022; 13 July 2023; 15 Jul 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) encourages applications for the Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) D43 program for institutional research training programs in low-and middle-income countries (LMICs, as defined by the World Bank classification system). Applications may be for collaborations between institutions in the U.S and an eligible LMIC or may involve just LMIC institutions if there is a previous track record of externally funded research and/or research training programs by the lead LMIC institution. The proposed institutional research training program is expected to sustainably strengthen the NCD research capacity of the LMIC institutions, and to train in-country experts to develop and conduct research on NCDs across the lifespan, with the long-range goal of developing and implementing evidence-based interventions relevant to their countries. Interdisciplinary research training that cuts across NCDs is encouraged. However, for more topical applications, the main focus of research training covered in the application must be relevant to the mission and/or interests of at least one of the participating NIH ICs, other than FIC, as stated by each in this FOA. Other NCD topics and types of training may be included as secondary and complementary focus areas. This Funding Opportunity Announcement (FOA) allows appointment of Trainees (D43) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budget: Application budgets are limited to \$230,000 per year for new awards and \$250,000 per year for renewal awards (total direct costs). The maximum project period is up to 5 years.

2. International Bioethics Research Training Program (D43 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-116](#)

Type: D43

Application Due Date: 7 June 2022; 6 June 2023; 6 June 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overall goal of this initiative is to support the mentored training of a sustainable critical mass of bioethics scholars in low and middle-income country (LMIC) research intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provide research ethics leadership to their institutions, governments and international research organizations. FIC will support LMIC-U.S. collaborative institutional bioethics doctoral and postdoctoral research training programs that incorporate mentored research, advanced theoretical didactic courses and ethics career skills training components to prepare multiple individuals for positions of ethics scholarship and leadership in health research institutions in LMICs. This Funding Opportunity Announcement (FOA) allows appointment of Trainees (D43) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budget: Applicants may request up to \$230,000 direct costs per year. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

3. International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-118](#)

Type: R25

Application Due Date: 7 June 2022; 6 June 2023; 6 June 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support the ethics of educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. (The overarching goal of this R25 program is to support educational activities that foster a better understanding of the ethics of biomedical, behavioral and clinical research and its implications.)

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on:

- **Courses for Skills Development**
- **Mentoring Activities**
- **Curriculum or Methods Development**
- **Research Experiences**

The Fogarty International Bioethics Training Program aims to increase the number of research intensive institutions in low- and middle-income countries (LMICs) that can provide advanced education in international research ethics. This FOA will support innovative LMIC master's level research ethics education programs proposing integrated activities to develop culturally appropriate foundational research ethics curriculum, research ethics career skills development courses, ethics research or practicum experiences, and effective mentoring approaches. Education programs supported by this initiative should equip scientists, health professionals and academics in these countries with in-depth knowledge of the ethical principles, processes and policies related to international research. Programs should be designed to strengthen the critical competencies needed to provide research ethics education, ethical review leadership and expert consultation to LMIC researchers, their academic or research institutions, governments and international health research organizations to enhance the application of research ethics principles.

Budget: Applications may request up to \$230,000 direct costs per year. The total project period may not exceed 5 years.

4. Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-123](#)

Type: U01

Application Due Date: 26 May 2022 through to 26 September 2024. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 – 10 years.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request \$500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

5. National Eye Institute (NEI) Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-135](#)

Type: R34

Application Due Date: 16 June 2022 through to 7 May 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Eye Institute (NEI) supports regenerative medicine clinical trials. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial's rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. The Regenerative Medicine Clinical Trial Planning Grant may be used by applicants to support the preparation of a clinical trial MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that restore vision in humans through regeneration of cells.

Budget: The NEI permits direct costs up to \$150,000 per year plus applicable F&A for consortia. The scope of the proposed project should determine the project period. The maximum period is two years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105